Cargando…

Epilepsy and psychosis– where are we now?

INTRODUCTION: Epilepsy has long been considered a risk factor for psychosis, and studies estimate that up to 80% of patients with epilepsy will experience a psychotic episode at some point in the course of their disease. However, data on the treatment of psychotic disorders in epilepsy is limited an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, I., Nogueira, V., Teixeira, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471233/
http://dx.doi.org/10.1192/j.eurpsy.2021.1378
_version_ 1784789025153875968
author Pereira, I.
Nogueira, V.
Teixeira, J.
author_facet Pereira, I.
Nogueira, V.
Teixeira, J.
author_sort Pereira, I.
collection PubMed
description INTRODUCTION: Epilepsy has long been considered a risk factor for psychosis, and studies estimate that up to 80% of patients with epilepsy will experience a psychotic episode at some point in the course of their disease. However, data on the treatment of psychotic disorders in epilepsy is limited and the management of these problems is still founded on individual clinical experience. OBJECTIVES: To assess evidence pertaining psychosis related to epilepsy, especially its risks factors and treatment approaches available. METHODS: Bibliographic research was made through the PubMed/NCBI database. No time limit was specified on the search. Pertinent manuscripts were individually reviewed for additional relevant citations. RESULTS: Recent literature shows a prevalence in psychotic disorders of 5.6%, and up to 7% in patients with epilepsy. So far, mechanisms of psychosis in epileptic patients remain unknown. Risk factors are earlier age of epilepsy onset, more frequent seizures, longer duration of epilepsy, high number of relatives with epilepsy and long-term antiepileptic drugs therapy. Psychiatric manifestations may include both positive and negative symptoms, including auditory hallucinations, paranoid delusions, and disorganized thought and/or behaviour. Poor adherence to treatment with oral antipsychotics occurs in more than 40% of patients; long-acting injectable medication should be considered, bearing in mind interactions with anti-epileptic medication and possibility of increased side effects. CONCLUSIONS: Our findings emphasize the importance of early recognition and management of psychosis in epileptic patients. Unfortunately, there is lack of evidence for the use of antipsychotic medication in epileptic patients, since available studies pertain to populations with primary psychiatric disorders.
format Online
Article
Text
id pubmed-9471233
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94712332022-09-29 Epilepsy and psychosis– where are we now? Pereira, I. Nogueira, V. Teixeira, J. Eur Psychiatry Abstract INTRODUCTION: Epilepsy has long been considered a risk factor for psychosis, and studies estimate that up to 80% of patients with epilepsy will experience a psychotic episode at some point in the course of their disease. However, data on the treatment of psychotic disorders in epilepsy is limited and the management of these problems is still founded on individual clinical experience. OBJECTIVES: To assess evidence pertaining psychosis related to epilepsy, especially its risks factors and treatment approaches available. METHODS: Bibliographic research was made through the PubMed/NCBI database. No time limit was specified on the search. Pertinent manuscripts were individually reviewed for additional relevant citations. RESULTS: Recent literature shows a prevalence in psychotic disorders of 5.6%, and up to 7% in patients with epilepsy. So far, mechanisms of psychosis in epileptic patients remain unknown. Risk factors are earlier age of epilepsy onset, more frequent seizures, longer duration of epilepsy, high number of relatives with epilepsy and long-term antiepileptic drugs therapy. Psychiatric manifestations may include both positive and negative symptoms, including auditory hallucinations, paranoid delusions, and disorganized thought and/or behaviour. Poor adherence to treatment with oral antipsychotics occurs in more than 40% of patients; long-acting injectable medication should be considered, bearing in mind interactions with anti-epileptic medication and possibility of increased side effects. CONCLUSIONS: Our findings emphasize the importance of early recognition and management of psychosis in epileptic patients. Unfortunately, there is lack of evidence for the use of antipsychotic medication in epileptic patients, since available studies pertain to populations with primary psychiatric disorders. Cambridge University Press 2021-08-13 /pmc/articles/PMC9471233/ http://dx.doi.org/10.1192/j.eurpsy.2021.1378 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Pereira, I.
Nogueira, V.
Teixeira, J.
Epilepsy and psychosis– where are we now?
title Epilepsy and psychosis– where are we now?
title_full Epilepsy and psychosis– where are we now?
title_fullStr Epilepsy and psychosis– where are we now?
title_full_unstemmed Epilepsy and psychosis– where are we now?
title_short Epilepsy and psychosis– where are we now?
title_sort epilepsy and psychosis– where are we now?
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471233/
http://dx.doi.org/10.1192/j.eurpsy.2021.1378
work_keys_str_mv AT pereirai epilepsyandpsychosiswherearewenow
AT nogueirav epilepsyandpsychosiswherearewenow
AT teixeiraj epilepsyandpsychosiswherearewenow